The one-time infusion, marketed as Breyanzi, is already approved in the US, Japan and Europe for the second-line treatment of relapsed or refractory large B-cell lymphoma, and in Japan, Europe and Canada for relapsed and refractory large B-cell lymphoma in the third-line setting. This latest expansion is for patients who have received at least two prior lines of therapy.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.